Forty Seven, Inc.

Forty Seven, Inc.

Forty Seven, Inc.

Overview
Date Founded

2014

Headquarters

1490 O'Brien Drive,Suite A,Menlo Park, CA 94025

Type of Company

Public

Employees (Worldwide)

51 - 100

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Website

http://www.fortyseveninc.com

Contact Data
Trying to get in touch with decision makers at Forty Seven, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
Business Wire
February 4, 2021
Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results; Fourth Quarter 2020 Year-Over-Year: - Product Sales increased 26% to $7.3 billion, primarily due to Veklury® (remdesivir) - - Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.1
Business Wire
December 30, 2020
Global Cancer Monoclonal Antibodies Market Report 2020-2030: COVID-19 Growth and Changes for the $45.4 Billion Industry - ResearchAndMarkets.com
GlobeNewswire
December 22, 2020
Global Cancer Monoclonal Antibodies Market Report 2020-2030: Focus on Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix)
GlobeNewswire
December 10, 2020
Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change
GlobeNewswire
December 2, 2020
Adagene Announces Expansion of Leadership Team to Support Strategic Growth

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
Executives & Employees
See More
Mark Chao

Co-Founder

Andrew Dickinson

President, Treasurer & Director

Craig Gibbs

Chief Business Officer

Chris H. Takimoto

Chief Medical Officer

Norman Kruse

Chief Patent Counsel

Kyle Elrod

Senior Vice President Planning & Operations

Jens-Peter Volkmer

Founder & Vice President Research & Early Development

Yasameen Qazen

Vice President, Regulatory Affairs & Quality Assurance

Aimee Murphy

Vice President Development Operations

Ravindra Majeti

Founder

Board of Directors
Brett A. Pletcher

Executive Vice President, Corporate Affairs & General Counsel at Gilead Sciences, Inc.

Andrew Dickinson

Executive Vice President & Chief Financial Officer at Gilead Sciences, Inc.

Christina Carlson

Director at Forty Seven, Inc.

Trending People
Shutterstock, Inc.
When you think climate change, you need to think about water - GreenBiz
Daimler AG
MORNING BID-It's time to talk about tax - Nasdaq
European Central Bank
FTSE 100 drops as surging pound dents exporters - City AM
HSBC Holdings Plc
Breaking: Extinction Rebellion activists target Lloyd's of London in the City - City AM
Greensill Capital (UK) Ltd.
Amid Inquiry, Credit Suisse Reports Loss - The New York Times
Trending Organizations
Shutterstock, Inc.
When you think climate change, you need to think about water - GreenBiz
Daimler AG
MORNING BID-It's time to talk about tax - Nasdaq
European Central Bank
FTSE 100 drops as surging pound dents exporters - City AM
HSBC Holdings Plc
Breaking: Extinction Rebellion activists target Lloyd's of London in the City - City AM
Greensill Capital (UK) Ltd.
Amid Inquiry, Credit Suisse Reports Loss - The New York Times
Paths to Forty Seven, Inc.
Potential Connections via
Relationship Science
You
Forty Seven, Inc.
Recent Transactions
Details Hidden

Gilead Sciences, Inc. purchases Forty Seven, Inc.

Details Hidden

Forty Seven, Inc. issued USD Common Stock

Details Hidden

Forty Seven, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent
American Stock Transfer & Trust Co. LLC

Advised onForty Seven, Inc. issued USD Common Stock

Legal Advisor
Cooley LLP

Advised onGilead Sciences, Inc. purchases Forty Seven, Inc.

Underwriter
Credit Suisse Securities (USA) LLC (Broker)

Advised onForty Seven, Inc. issued USD Common Stock

Managing Director
Connie Chiang

Advised onForty Seven, Inc. issued USD Common Stock

Legal Advisor
Eric C. Jensen

Advised onGilead Sciences, Inc. purchases Forty Seven, Inc.

Legal Advisor
John Mckenna

Advised onGilead Sciences, Inc. purchases Forty Seven, Inc.

Advisors & Consultants
Legal Advisor
Eric C. Jensen

Partner, Palo Alto at Cooley LLP

Legal Advisor
John Mckenna

Partner, Palo Alto at Cooley LLP

Advisor
Alan Hartman

Partner at Centerview Partners LLC
Clients
Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
Key Stats and Financials As of
Market Capitalization
$4.6B
Total Enterprise Value
Earnings Per Share
Investors
Details Hidden
Wellington Management Co. LLP (Private Equity)

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden
Jens-Peter Volkmer

Founder & Vice President Research & Early Development at Forty Seven, Inc.

Details Hidden
Ravindra Majeti

Associate Professor at Stanford University

Suppliers
Stanford University Biotechnology | Redwood City, usa

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Lonza Group AG Pharmaceuticals | Basel, Che

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Pharma & Biotech; Specialty Ingredients; and Corporate. The Pharma & Biotech segment comprises development and manufacture of customized active pharmaceutical ingredients and biopharmaceuticals as well as formulation services and delivery systems. The Specialty Ingredients segment consists of two divisions, consumer health and consumer resources and protection. The Corporate segment includes corporate functions, such as finance and accounting, legal, communication, information technology, and human resources. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Biotechpharma UAB Pharmaceuticals

Biotechpharma UAB is a private company headquartered in Lithuania that operates contract development and manufacturing organization (CDMO) for biopharmaceuticals.

Competitors
Stanford University Investment Services & Portfolio Management - Redwood City, usa

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Forty Seven, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Forty Seven, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Forty Seven, Inc..